Skip to main content

Table 1 Characteristics of patients treated on E2603 included in this analysis

From: MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

 

n = 115

Characteristic

n (%)

Male sex

77 (67.0)

Median age, years (range)

59 (23–82)

AJCC stage

 

 Unresectable stage III

16 (13.9)

 M1a/M1b

41 (35.7)

 M1c

58 (50.4)

Serum LDH at baseline

 

 Normal

65 (56.5)

 Above normal

47 (40.9)

ECOG performance status

 

 0

67 (58.3)

 1

48 (41.7)

Prior systemic therapy

 

 None

52 (45.2)

 Interferon, IL-2, GM-CSF

59 (51.3)

 Investigational therapy

4 (3.5)

Treatment arm

 

 Carboplatin/paclitaxel

58 (50.4)

 Carboplatin/paclitaxel/sorafenib

57 (49.6)

BRAF status

 

 Mutant

48 (41.8)

 V600E

34 (29.6)

 V600K

8 (7.0)

 V600R

3 (2.6)

 V600D

1 (0.9)

 K601E

2 (1.7)

 Wild-type

52 (45.2)

 Unknown

15 (13.0)

NRAS status

 

 Mutant

22 (19.1)

 G13R

2 (1.7)

 G13C

1 (0.9)

 Q61R

9 (7.8)

 Q61K

8 (7.0)

 D61L

2 (1.7)

 Wild-type

78 (67.8)

 Unknown

15 (13.0)

Survival

 

 Median OS, months (range)

9.8 (0.5–56.9)

 Median PFS, months (range)

4.4 (0.5–42.1)